<DOC>
	<DOCNO>NCT02588937</DOCNO>
	<brief_summary>The purpose study evaluate antiviral activity safety EntecaBell ODT . chronic hepatitis B Patients .</brief_summary>
	<brief_title>Active Drug Comparative Trial Evaluate Antiviral Activity Safety Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Over age 20 year old 2 . Patients Chronic Hepatitis B diagnose 3 . Patients show positive HBsAg 4 . Patients show positive HBeAg negative HBeAg 5 . Patients show HBV DNA undetected ( less 300 copies/mL ) 6 . Patients administer Baraclude Tab . 0.5mg 1~4 year 7 . Patients show ALT le 5 time upper limit normal range 8 . Patient decide participate sign informed consent form willingly 1 . Patients hepatitis C ( HCV ) , hepatitis D ( HDV ) , human immunodeficiency virus ( HIV ) 2 . Patients uncompensated liver disease least one follow value sign Total bilirubin &gt; 2.5mg/dl Prothrombin time delay three second upper limit normal range Serum Albumin &lt; 3 g/dL A medical history ascites , jaundice , hemorrhage varix , hepatic encephalopathy , sign liver function loss 3 . Patients estimate hepatocellular carcinoma ( HCC ) image examination show alphafetoprotein ( AFP ) 100 ng/mL 4 . Patients show Creatinine Clearance &lt; 50 mL/min calculate CockcroftGault equation 5 . Patients administered antiviral agent except Baraclude Tab . ( Entecavir ) 6 . Administration Investigational Product within 30 day 7 . History malignant tumor within 5 year ( include leukemia lymphoma ) 8 . Patients severe disease , heart failure , renal failure , pancreatitis , decide investigator effect clinical trial 9 . Patients hepatic disease except hepatitis B 10 . Administration immunosuppressant corticosteroids 2 week within 24 week 11 . Patients administer immunosuppressant Nephrotoxic drug , Hepatotoxic drug period Clinical Trial 12 . Pregnant , breastfeed childbearing age n't use adequate contraception 13 . Patients possible decline daily function due mental disease patient able understand purpose method clinical trial 14 . Patients receive organ transplant go receive organ transplant 15 . Severe hypersensitivity Entecavir 16 . Another clinical condition investigator 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Entecavir , EntecaBell ODT. , Hepatitis B</keyword>
</DOC>